Gemsitabin (Turkish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gemsitabin" in Turkish language version.

refsWebsite

Global rank Turkish rank

16doi.org

2^nd place

4^th place

16nih.gov

4^th place

11^th place

15web.archive.org

1^st place

2books.google.com

3^rd place

5^th place

1drugs.com

399^th place

156^th place

1cancercareontario.ca

low place

1cancer.gov

1,684^th place

2,339^th place

1fiercebiotech.com

low place

1news-medical.net

8,069^th place

6,420^th place

1medicines.org.uk

3,823^rd place

3,999^th place

1fda.gov

447^th place

858^th place

1macmillan.org.uk

low place

1archive.org

6^th place

1soton.ac.uk

6,219^th place

low place

1europa.eu

68^th place

79^th place

1fiercepharma.com

low place

1missouri.edu

3,342^nd place

9,047^th place

1seekingalpha.com

5,344^th place

low place

1cancernetwork.com

low place

archive.org

Rachel Airley (2009). Cancer Chemotherapy. Wiley-Blackwell. ISBN 978-0-470-09254-5.

books.google.com

Analogue-based Drug Discovery. John Wiley & Sons. 2006. s. 511. ISBN 9783527607495. 12 Ocak 2023 tarihinde kaynağından arşivlendi. Erişim tarihi: 30 Aralık 2022.
"Analysis of Cases on Pharmaceutical Patent Infringement in Great China". Law, Politics and Revenue Extraction on Intellectual Property (İngilizce). Cambridge Scholars Publishing. 2015. s. 119. ISBN 9781443879262. 11 Eylül 2017 tarihinde kaynağından arşivlendi.

cancer.gov

"FDA Approval for Gemcitabine Hydrochloride". National Cancer Institute. 5 Ekim 2006. 5 Nisan 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 22 Nisan 2017.

cancercareontario.ca

"Drug Formulary/Drugs/ gemcitabine - Provider Monograph". Cancer Care Ontario. 24 Şubat 2019 tarihinde kaynağından arşivlendi. Erişim tarihi: 6 Aralık 2020.

cancernetwork.com

"Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer". Oncology. 31 (3): 159-66, 168. March 2017. PMID 28299752. 3 Temmuz 2017 tarihinde kaynağından arşivlendi.

doi.org

"Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation". Antiviral Research. 184: 104967. December 2020. doi:10.1016/j.antiviral.2020.104967. PMID 33137361. KB1 bakım: göster-yazarlar (link)
"Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis". Targeted Oncology. 12 (3): 309-321. June 2017. doi:10.1007/s11523-017-0486-5. PMID 28353074.
"Systemic Therapy of Cholangiocarcinoma". Visceral Medicine. 32 (6): 427-430. December 2016. doi:10.1159/000453084. PMC 5290432 $2. PMID 28229078.
"Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice". Current Treatment Options in Oncology. 17 (11): 58. November 2016. doi:10.1007/s11864-016-0432-2. PMID 27658789.
"Capillary leak syndrome: etiologies, pathophysiology, and management". Kidney International. 92 (1): 37-46. July 2017. doi:10.1016/j.kint.2016.11.029. PMID 28318633.
"Thrombotic thrombocytopenic purpura and gemcitabine". Case Reports in Oncology. 4 (1): 143-148. January 2011. doi:10.1159/000326801. PMC 3114619 $2. PMID 21691573.
"PharmGKB summary: gemcitabine pathway". Pharmacogenetics and Genomics. 24 (11): 564-574. November 2014. doi:10.1097/fpc.0000000000000086. PMC 4189987 $2. PMID 25162786. KB1 bakım: göster-yazarlar (link)
"Cellular pharmacology of gemcitabine". Annals of Oncology. 17 (Suppl 5): v7-12. May 2006. doi:10.1093/annonc/mdj941. PMID 16807468.
Fatima, M., Iqbal Ahmed, M. M., Batool, F., Riaz, A., Ali, M., Munch-Petersen, B., & Mutahir, Z. (2019). Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells. Bosnian Journal of Basic Medical Sciences, 19(4), 342-349. https://doi.org/10.17305/bjbms.2019.4136
"Understanding ribonucleotide reductase inactivation by gemcitabine". Chemistry: A European Journal. 13 (30): 8507-8515. 2007. doi:10.1002/chem.200700260. PMID 17636467.
"A linear synthesis of gemcitabine". Carbohydrate Research. 406: 71-75. April 2015. doi:10.1016/j.carres.2015.01.001. PMID 25681996.
"The synthesis of gemcitabine". Carbohydrate Research. 387: 59-73. March 2014. doi:10.1016/j.carres.2014.01.024. PMID 24636495.
"Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy". Critical Reviews in Therapeutic Drug Carrier Systems. 34 (1): 63-96. 2017. doi:10.1615/CritRevTherDrugCarrierSyst.2017017912. PMID 28322141.
"Nanotechnology for delivery of gemcitabine to treat pancreatic cancer". Biomedicine & Pharmacotherapy. 88: 635-643. April 2017. doi:10.1016/j.biopha.2017.01.071. PMID 28142120.
"Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine". European Journal of Pharmaceutical Sciences. 93: 147-162. October 2016. doi:10.1016/j.ejps.2016.08.021. PMID 27531553.
"Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities". Current Opinion in Oncology. 23 (5): 463-468. September 2011. doi:10.1097/cco.0b013e328349428d. PMC 3465839 $2. PMID 21681092.

drugs.com

"Gemcitabine Hydrochloride". The American Society of Health-System Pharmacists. 2 Şubat 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 8 Aralık 2016.

europa.eu

ema.europa.eu

"Gemzar" (İngilizce). European Medicines Agency. 24 Eylül 2008. 11 Eylül 2017 tarihinde kaynağından arşivlendi.

fda.gov

accessdata.fda.gov

"US formLabel" (PDF). FDA. June 2014. 16 Şubat 2017 tarihinde kaynağından (PDF) arşivlendi. Erişim tarihi: 6 Mayıs 2017. For label updates see FDA index page for NDA 020509 29 Nisan 2017 tarihinde Wayback Machine sitesinde arşivlendi.

fiercebiotech.com

"Gemcitabine from Actavis launched on patent expiry in EU markets". FierceBiotech (İngilizce). 13 Mart 2009. 11 Eylül 2017 tarihinde kaynağından arşivlendi.

fiercepharma.com

"Patent for Lilly's cancer drug Gemzar invalidated". FiercePharma (İngilizce). 18 Ağustos 2009. 11 Eylül 2017 tarihinde kaynağından arşivlendi.

macmillan.org.uk

"Gemcitabine". Macmillan Cancer Support. 25 Mart 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 6 Mayıs 2017.

medicines.org.uk

"UK label" (İngilizce). UK Electronic Medicines Compendium. 5 Haziran 2014. 10 Temmuz 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 6 Mayıs 2017.

missouri.edu

law.missouri.edu

"Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation" (PDF). Missouri Law Review. 76 (3): 645-693. Yaz 2011. 11 Eylül 2017 tarihinde kaynağından (PDF) arşivlendi. Erişim tarihi: 6 Mayıs 2017.

news-medical.net

"Press release: Hospira launches two-gram vial of gemcitabine hydrochloride for injection" (İngilizce). Hospira via News-Medical.Net. 16 Kasım 2010. 2 Ekim 2015 tarihinde kaynağından arşivlendi.

nih.gov

ncbi.nlm.nih.gov

"Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation". Antiviral Research. 184: 104967. December 2020. doi:10.1016/j.antiviral.2020.104967. PMID 33137361. KB1 bakım: göster-yazarlar (link)
"Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis". Targeted Oncology. 12 (3): 309-321. June 2017. doi:10.1007/s11523-017-0486-5. PMID 28353074.
"Systemic Therapy of Cholangiocarcinoma". Visceral Medicine. 32 (6): 427-430. December 2016. doi:10.1159/000453084. PMC 5290432 $2. PMID 28229078.
"Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice". Current Treatment Options in Oncology. 17 (11): 58. November 2016. doi:10.1007/s11864-016-0432-2. PMID 27658789.
"Capillary leak syndrome: etiologies, pathophysiology, and management". Kidney International. 92 (1): 37-46. July 2017. doi:10.1016/j.kint.2016.11.029. PMID 28318633.
"Thrombotic thrombocytopenic purpura and gemcitabine". Case Reports in Oncology. 4 (1): 143-148. January 2011. doi:10.1159/000326801. PMC 3114619 $2. PMID 21691573.
"PharmGKB summary: gemcitabine pathway". Pharmacogenetics and Genomics. 24 (11): 564-574. November 2014. doi:10.1097/fpc.0000000000000086. PMC 4189987 $2. PMID 25162786. KB1 bakım: göster-yazarlar (link)
"Cellular pharmacology of gemcitabine". Annals of Oncology. 17 (Suppl 5): v7-12. May 2006. doi:10.1093/annonc/mdj941. PMID 16807468.
"Understanding ribonucleotide reductase inactivation by gemcitabine". Chemistry: A European Journal. 13 (30): 8507-8515. 2007. doi:10.1002/chem.200700260. PMID 17636467.
"A linear synthesis of gemcitabine". Carbohydrate Research. 406: 71-75. April 2015. doi:10.1016/j.carres.2015.01.001. PMID 25681996.
"The synthesis of gemcitabine". Carbohydrate Research. 387: 59-73. March 2014. doi:10.1016/j.carres.2014.01.024. PMID 24636495.
"Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy". Critical Reviews in Therapeutic Drug Carrier Systems. 34 (1): 63-96. 2017. doi:10.1615/CritRevTherDrugCarrierSyst.2017017912. PMID 28322141.
"Nanotechnology for delivery of gemcitabine to treat pancreatic cancer". Biomedicine & Pharmacotherapy. 88: 635-643. April 2017. doi:10.1016/j.biopha.2017.01.071. PMID 28142120.
"Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine". European Journal of Pharmaceutical Sciences. 93: 147-162. October 2016. doi:10.1016/j.ejps.2016.08.021. PMID 27531553.
"Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer". Oncology. 31 (3): 159-66, 168. March 2017. PMID 28299752. 3 Temmuz 2017 tarihinde kaynağından arşivlendi.
"Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities". Current Opinion in Oncology. 23 (5): 463-468. September 2011. doi:10.1097/cco.0b013e328349428d. PMC 3465839 $2. PMID 21681092.

seekingalpha.com

"On the Generic Gemzar Patent Fight". Seeking Alpha. 28 Temmuz 2010. 9 Aralık 2012 tarihinde kaynağından arşivlendi.

soton.ac.uk

eprints.soton.ac.uk

"The synthesis of gemcitabine". Carbohydrate Research. 387: 59-73. March 2014. doi:10.1016/j.carres.2014.01.024. PMID 24636495.

web.archive.org

"Gemcitabine Hydrochloride". The American Society of Health-System Pharmacists. 2 Şubat 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 8 Aralık 2016.
"Drug Formulary/Drugs/ gemcitabine - Provider Monograph". Cancer Care Ontario. 24 Şubat 2019 tarihinde kaynağından arşivlendi. Erişim tarihi: 6 Aralık 2020.
"FDA Approval for Gemcitabine Hydrochloride". National Cancer Institute. 5 Ekim 2006. 5 Nisan 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 22 Nisan 2017.
Analogue-based Drug Discovery. John Wiley & Sons. 2006. s. 511. ISBN 9783527607495. 12 Ocak 2023 tarihinde kaynağından arşivlendi. Erişim tarihi: 30 Aralık 2022.
"Gemcitabine from Actavis launched on patent expiry in EU markets". FierceBiotech (İngilizce). 13 Mart 2009. 11 Eylül 2017 tarihinde kaynağından arşivlendi.
"Press release: Hospira launches two-gram vial of gemcitabine hydrochloride for injection" (İngilizce). Hospira via News-Medical.Net. 16 Kasım 2010. 2 Ekim 2015 tarihinde kaynağından arşivlendi.
"UK label" (İngilizce). UK Electronic Medicines Compendium. 5 Haziran 2014. 10 Temmuz 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 6 Mayıs 2017.
"US formLabel" (PDF). FDA. June 2014. 16 Şubat 2017 tarihinde kaynağından (PDF) arşivlendi. Erişim tarihi: 6 Mayıs 2017. For label updates see FDA index page for NDA 020509 29 Nisan 2017 tarihinde Wayback Machine sitesinde arşivlendi.
"Gemcitabine". Macmillan Cancer Support. 25 Mart 2017 tarihinde kaynağından arşivlendi. Erişim tarihi: 6 Mayıs 2017.
"Gemzar" (İngilizce). European Medicines Agency. 24 Eylül 2008. 11 Eylül 2017 tarihinde kaynağından arşivlendi.
"Patent for Lilly's cancer drug Gemzar invalidated". FiercePharma (İngilizce). 18 Ağustos 2009. 11 Eylül 2017 tarihinde kaynağından arşivlendi.
"Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation" (PDF). Missouri Law Review. 76 (3): 645-693. Yaz 2011. 11 Eylül 2017 tarihinde kaynağından (PDF) arşivlendi. Erişim tarihi: 6 Mayıs 2017.
"On the Generic Gemzar Patent Fight". Seeking Alpha. 28 Temmuz 2010. 9 Aralık 2012 tarihinde kaynağından arşivlendi.
"Analysis of Cases on Pharmaceutical Patent Infringement in Great China". Law, Politics and Revenue Extraction on Intellectual Property (İngilizce). Cambridge Scholars Publishing. 2015. s. 119. ISBN 9781443879262. 11 Eylül 2017 tarihinde kaynağından arşivlendi.
"Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer". Oncology. 31 (3): 159-66, 168. March 2017. PMID 28299752. 3 Temmuz 2017 tarihinde kaynağından arşivlendi.